ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?
Chemotherapy-induced activation of ADAM-17 results in increased growth factor shedding and activation of growth factor receptor-mediated pro-survival response. Enhanced ADAM-17 activity and HER ligand shedding results in resistance to chemotherapy in CRC. Therapies that decrease ADAM-17 activity in conjunction with current treatments may enhance response rates in advanced CRC patients.
Version: za2963e q8za1 q8zbe q8zc6 q8zdb q8zed q8zf1 q8zgd